Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has implemented a public whistleblower policy offering cash rewards of up to USD $7 million for verifiable evidence of stock manipulation involving the company's shares. The biopharmaceutical company, which focuses on treatments for neurodegenerative, metabolic, and alcohol misuse disorders, will pay the reward from the net proceeds of its ongoing lawsuit against parties allegedly involved in market manipulation activities.
The whistleblower program allows eligible participants to submit information directly to reward@quantumbiopharma.com or by calling 1-833-571-1811. The substantial reward will be granted only if the submitted information materially contributes to a final, non-appealable judgment or binding settlement in Quantum BioPharma's favor. This initiative was approved by the company's board and audit committee with input from multiple law firms, demonstrating the formal legal foundation supporting the program.
This whistleblower policy underscores Quantum BioPharma's commitment to transparency, accountability, and market integrity while encouraging simultaneous reporting to both U.S. and Canadian regulatory authorities. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Additional information about the company is available in its newsroom at https://ibn.fm/QNTM.
The announcement was distributed through InvestorWire, a specialized communications platform that provides advanced wire-grade press release syndication as part of the Dynamic Brand Portfolio @ IBN. InvestorWire delivers access to a vast network of wire solutions and article syndication to 5,000+ outlets, along with enhanced press release services and social media distribution. Full terms of use and disclaimers are available on the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
Quantum BioPharma's whistleblower program represents one of the largest financial incentives ever offered by a publicly traded company specifically targeting stock manipulation. The company's lead compound, Lucid-MS, developed through its wholly owned subsidiary Lucid Psycheceuticals Inc., represents a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The implementation of this whistleblower policy occurs as the company continues advancing its pharmaceutical pipeline while addressing potential market integrity concerns through both legal and regulatory channels.
